Nebenwirkungen · Jemperli
JEMPERLI 500 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 14
HOS-145374 · Präparat HOS-099336
Of the 605 patients treated with dostarlimab monotherapy, 51.6 % were under 65 years, 36.9 % were 65 to less than 75 years, and 11.5 % were 75 years or older. Of the 241 patients treated with dostarlimab in combination with carboplatin-paclitaxel, 52.3% were under 65 years, 36.5% were 65 to less than 75 years, and 11.2% were 75 years or older. No overall differences in safety were reported between elderly (≥ 65 years) and younger patients (< 65 years).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T11:00:00Z · SHA-256 c9cfea3ac27190f9161acc3184a04c8f1d0df0ea11733d3f3f64b1b633b93895 · Passage 81028d71fe3451367704d42eb2f13588b15ff0ebdb667d5df9f482c7b936fd10 · Zeichen 14552–15008 im Abschnitt